EGFR and cancer: Three generations of small molecule EGFR inhibitors have been approved by the United States Food and Drug Administration (US FDA) to treat non‐small cell lung cancer (NSCLC) and other human cancers, severe resistance in clinical patients due to persistent isomerism mutations (EGFRC797S) remains an insurmountable problem for these inhibitors.